Novo Nordisk’s once-weekly Sogroya (somapacitan) has proved to be non-inferior to the once-daily growth hormone Norditropin (somatropin) in children’s growth disorders in a Phase III trial ...

Sogroya showed 11.0 cm/year growth in SGA children vs 9.4 cm/year with low-dose somatropin and 11.1 cm/year with high-dose. In Noonan syndrome, Sogroya achieved 10.4 cm/year height gain vs 9.2 cm ...

March 5, 2010 — The US Food and Drug Administration (FDA) has approved a prefilled somatropin (rDNA origin) injection pen (Norditropin FlexPro, Novo Nordisk, Inc) for the treatment of growth ...

Novo Nordisk reported positive data from a late-stage trial of its once-weekly Sogroya treatment for children with growth disorders. The Danish pharmaceutical giant said the drug was more ...

Sogroya is meant to succeed Novo’s once-a-day growth hormone Norditropin, which has now been on the market for decades. Eli Lilly, Merck & Co. and Pfizer all sell their own daily growth disorder ...

Novo Nordisk's Sogroya Shows Tolerability In Children With Growth Disorders May 12, 2025 — 07:44 am EDT Written by RTTNews.com for RTTNews -> ...

Findings showed that somapacitan was noninferior to somatropin for improving yearly growth rate, based on height velocity (HV) at week 52 (primary endpoint) in children born SGA, or with NS or ISS.